Skip to main content
. Author manuscript; available in PMC: 2023 Aug 16.
Published in final edited form as: Mod Pathol. 2019 Sep 4;33(2):281–296. doi: 10.1038/s41379-019-0352-3

Fig. 4.

Fig. 4

a Epithelioid localized malignant mesothelioma. The tumor cells exhibit strong nuclear and cytoplasmic immunoreactivity for calretinin (PAP, 100×). b Epithelioid localized malignant mesothelioma. The tumor cells exhibit nuclear immunoreactivity for WT-1 (PAP, 100×)